

Meeting Minutes
North Dakota Medicaid Drug Use Review (DUR) Board
Meeting Date: March 5th, 2025
Time and Location: 1:00 pm CST in Bismarck, North Dakota

Call to Order:

A regular quarterly meeting of the North Dakota Medicaid Drug Use Review (DUR) Board meeting was convened at 1:06 pm CST with K. Martian presiding as Presiding Officer. DUR Board Coordinator, J. McKee recording minutes.

Roll Call:

Board Members Voting:

Present: Stephanie Antony, Gabriela Balf, Amanda Dahl, Kurt Datz, Andrea Honeyman, Laura Kroetsch, Kevin Martian, Kristen Peterson, Amy Werremeyer, Jessica Ziegler, Matthew Zimny

Absent: Tanya Schmidt

Quorum Present: Yes

Board Members Non-Voting: Kathleen Traylor

Absent:

Medicaid Pharmacy Department:

Present: Jeff Hostetter, Brendan Joyce, Alexi Murphy, Katie Steig

Absent: LeNeika Roehrich

Approval of Meeting Minutes:

Motion: Moved by K. Datz to approve the minutes of the December 4th, 2024, meeting, motion was seconded by K. Martian. **Motion carried.**

The minutes of the December 4th, 2024, meeting were approved as distributed.

Reports:

Financial Report: Budget provided by B. Joyce

B. Joyce shared with the Board trends of reimbursement amount vs net spend for pharmacy drug claims. This information can be found in the handout.

Financial Report: Top Drugs provided by B. Joyce

B. Joyce presented the quarterly review of the top 25 drugs based on total number and cost of claims and the top 15 therapeutic classes based on number and cost of claims. This report can be found in the handout.

Retrospective Drug Utilization Review (RDUR) Report by J. McKee

J. McKee reviewed the quarterly RDUR criteria that were selected for review of each month and information from a targeted mailing. This material can be found in the handout.

Clinical Report and Annual PDL Review: Prior Authorization and Criteria Updates by J. McKee

J. McKee presented prior authorization and criteria updates with emphasis on the following sections in the PDL: Amyloidosis, GLP-1 Receptor Agonist Combinations, Metabolic Dysfunction-Associated Steatohepatitis, Parkinson's Disease. Testimony was provided by Shawn Hanse from Novo Nordisk on Ozempic, Tara McKinley from Madrigal Pharmaceuticals on Rezdiffra, and Christine Dube from Astrazeneca on Airsupra.

Unfinished business: provided by J. McKee

J. McKee provided updates on alternative RDUR communication tools. The presented material can be found in the handout.

New business:

First Reviews presented by J. McKee

J. McKee presented an overview of diabetes mellitus. The presented material can be found in the handout.

Motion: Moved by K. Martian to draft prior authorization for diabetes mellitus, motion was seconded by A. Werremeyer. **Motion carried.**

Second Reviews presented by J. McKee

J. McKee presented group prior authorization criteria for Migraine Prophylaxis and Treatment. Testimony was provided by Jasmine Inman from Teva on Ajovy.

Motion: Moved by K. Datz to place Migraine Prophylaxis and Treatment on prior authorization, motion was seconded by K. Martian. **Motion carried.**

J. McKee presented group prior authorization criteria for Nonsteroidal Anti-Inflammatory Drugs.

Motion: Moved by A. Werremeyer to place Nonsteroidal Anti-Inflammatory Drugs on prior authorization, motion was seconded by A. Dahl. **Motion carried.**

J. McKee presented group prior authorization criteria for Primary Biliary Cholangitis.

Motion: Moved by K. Martian to place Primary Biliary Cholangitis on prior authorization, motion was seconded by K. Datz. **Motion carried.**

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations:

RDUR criteria recommendations were reviewed. The presented material can be found in the handout.

Motion: Moved by K. Martian to approve the RDUR criteria, motion was seconded by K. Datz. **Motion carried.**

Announcements:

Next meeting is June 4th, 2025.

Adjournment:

Meeting adjourned by K. Martian at 1:54 pm CST.

Date of Minutes Approval: June 4, 2025

Minutes submitted by: Julie McKee, Acentra Health